Fierce Biotech1 min read
saveCrown Biosciences stays put as $204M Adicon deal falls through
Crown Biosciences looks destined to go unworn for a while longer after its planned $204 million acquisition by China's Adicon fell through.
Crown Biosciences looks destined to go unworn for a while longer after its planned $204 million acquisition by China's Adicon fell through.
comments(0)
5-min edit window · permanent after that